Home » Stocks » Pliant Therapeutics

Pliant Therapeutics, Inc. (PLRX)

Stock Price: $24.00 USD 0.11 (0.46%)
Updated Sep 22, 2020 12:47 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 850.66M
Revenue (ttm) 89.59M
Net Income (ttm) 22.94M
Shares Out 35.44M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Sep 22, 2020
Last Price $24.00
Previous Close $23.89
Change ($) 0.11
Change (%) 0.46%
Day's Open 24.19
Day's Range 22.17 - 24.80
Day's Volume 72,484
52-Week Range 21.05 - 35.63

More Stats

Market Cap 850.66M
Enterprise Value 538.19M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 35.44M
Float 25.37M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 159,001
Short Ratio 8.18
Short % of Float 2.26%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 9.49
PB Ratio 3.10
Revenue 89.59M
Operating Income n/a
Net Income 22.94M
Free Cash Flow n/a
Net Cash 312.47M
Net Cash / Share 8.82
Gross Margin 63.68%
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA 12.56%
ROE 22.15%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(80.54% upside)
Current: $24.00
Target: 43.33
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Gross Profit57.05-
Operating Income-1.23-30.92
Net Income-0.63-30.28
Shares Outstanding1.621.17
Earnings Per Share-4.22-30.16
Operating Cash Flow-2.75-28.33
Capital Expenditures-0.96-2.32
Free Cash Flow-3.71-30.65
Cash & Equivalents10360.95
Net Cash / Debt10360.95
Book Value-76.30-71.47
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Pliant Therapeutics, Inc.
Country United States
Employees 67
CEO Bernard Coulie

Stock Information

Ticker Symbol PLRX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PLRX
IPO Date June 3, 2020


Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrotic in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which has completed Phase Ia single ascending dose/ multiple ascending dose trails and Phase Ib proof-of-mechanism trials for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company also develops PLN-1474, small-molecule selective inhibitor of avß1, which is Phase 1 clinical trials for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. Pliant Therapeutics, Inc. was founded in 2015 and is based in South San Francisco, California.